Alvotech - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALVO Nasdaq 2836 www.alvotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alvotech

Alvotech (ALVO): A Bull Case Theory - Dec 4th, 2025 11:39 am
Alvotech (ALVO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Regulatory Challenges - Nov 24th, 2025 6:01 pm
Alvotech's (NASDAQ:ALVO) Performance Raises Some Questions - Nov 24th, 2025 12:50 pm
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area - Nov 24th, 2025 3:30 am
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - Nov 20th, 2025 2:00 am
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Nov 16th, 2025 5:23 am
Alvotech (ALVO) Reports Q3 Loss, Misses Revenue Estimates - Nov 12th, 2025 3:55 pm
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update - Nov 12th, 2025 2:40 pm
European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown - Nov 10th, 2025 10:22 am
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept) - Nov 10th, 2025 2:00 am
Alvotech (ALVO) Is Down 35.5% After FDA Delays Key AVT05 Biosimilar Approval—Has The Bull Case Changed? - Nov 7th, 2025 11:12 am
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - Nov 7th, 2025 6:10 am
Can Alvotech’s Sharp 61% Drop Signal a Value Opportunity After Regulatory Updates? - Nov 7th, 2025 4:12 am
How Recent Developments Are Rewriting the Story for Alvotech - Nov 6th, 2025 7:09 pm
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA - Nov 6th, 2025 7:07 am
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates - Nov 6th, 2025 6:30 am
Analysts Estimate Alvotech (ALVO) to Report a Decline in Earnings: What to Look Out for - Nov 5th, 2025 8:00 am
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates - Nov 5th, 2025 6:15 am
Alvotech (NASDAQ:ALVO) Analysts Just Slashed This Year's Revenue Estimates By 11% - Nov 5th, 2025 4:00 am
Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update - Nov 4th, 2025 2:01 pm